Entry of HIV in Primary Human Resting CD4$^+$ T Cells Pretreated with the Chemokine CCL19

Jenny L. Anderson$^{1,2}$ Karey Cheong$^{1,2}$ Amas K.H. Lee$^{1,2}$ Suha Saleh$^{1,2}$ Candida da Fonseca Pereira$^{2-4}$ Paul U. Cameron$^{1,2,4}$ and Sharon R. Lewin$^{1,2,4}$

Resting CD4$^+$ T cells latently infected with HIV are a major barrier to a cure and therefore antiretroviral therapy is required life-long. There are two major potential pathways leading to the establishment of latency. One pathway, which we refer to as postactivation latency, occurs with the reversion of an activated infected CD4$^+$ T cell to the resting memory state with an integrated silenced provirus. The other pathway, preactivation latency, occurs via direct infection of resting CD4$^+$ T cells. The relative contribution in vivo of preactivation and postactivation latency is unclear, but latency can be established in vitro via both pathways.$^1$

$^1$Department of Infectious Diseases, Monash University, Victoria, Australia.
$^2$Centre for Biomedical Research, Burnet Institute, Victoria, Australia.
$^3$Monash Micro Imaging, Monash University, Victoria, Australia.
$^4$Department of Infectious Diseases, Alfred Hospital, Victoria, Australia.
We have previously demonstrated that although unstimulated resting CD4\(^+\) T cells are relatively resistant to HIV infection, incubation of resting CD4\(^+\) T cells with chemokines that bind the chemokine receptors, CCR7, CXCR3, and CCR6, which are all highly expressed on resting CD4\(^+\) T cells, facilitates latent infection in vitro.\(^2,3\) Pretreatment with the chemokine CCL19, the ligand for CCR7, facilitated rapid nuclear localization and efficient integration. This was in part mediated via CCL19-induced changes in the actin cytoskeleton.\(^3\) Our aim here was to visualize the early events following HIV entry into a resting CD4\(^+\) T cell.

We used fluorescent HIV to infect CCL19-treated resting CD4\(^+\) T cells to track the migration of virus to the nucleus. Resting CD4\(^+\) T cells were incubated with 30 nM CCL19 and infected at an MOI of 0.1 with HIVNL4.3 that was dual labeled with green fluorescent protein (GFP) fused to HIV Vpr and S15tomato fused to the viral membrane. GFPVpr associates with HIV cores and tracks HIV complexes in the cytoplasm of target cells. S15tomato is a fluorescent variant of S15mCherry that is no longer visible when virus particles fuse to target cells.\(^4\) Therefore, HIV that has fused and entered a cell can be identified as GFPVpr\(^+\) S15tomato\(^-\).

Two hours after the addition of virus, cells were fixed and filamentous actin (F-actin) was stained using Alexa Fluor 350.phalloidin (Molecular Probes). The cells were placed in a Labtek II chamber slide and images were captured in a z series using a CoolSNAP camera (Photometrics) on a DeltaVision microscope (100\(\times\)1.4 numerical aperture oil immersion lens, Applied Precision). Images were deconvolved using softWoRx deconvolution software (Applied Precision). A single z section of a deconvolved image is shown. Cells were also cultured for 4 days and quantification of integrated DNA was performed using Alu-LTR real time PCR.\(^3\) Reverse transcriptase (RT) was quantified in supernatant. The frequency of integrated HIV was 92,000 copies/\(10^6\) CD4\(^+\) T cells and there was minimal RT production consistent with latent infection.

In the image shown in Fig. 1, fused HIV complexes (GFPVpr\(^+\) S15tomato\(^-\)) that have penetrated cortical F-actin at the cell periphery and are located in the resting CD4\(^+\) T cell cytoplasm can be seen. We are now examining how HIV interacts with other components of the cell cytoskeleton and defining key cellular proteins required for rapid transit of HIV to the nucleus in CCL19-treated resting CD4\(^+\) T cells.

Acknowledgments

The authors acknowledge the facilities and scientific and technical assistance of Monash Micro Imaging, Monash University, Victoria, Australia. This research was supported by NIH Bridging Grant 1R56AI95073-1A1 and a U19 Grant to the DARE Collaboratory AI096109.

References


Address correspondence to:
Sharon R. Lewin
Department of Infectious Diseases
Monash University
Level 2 Burnet Institute
85 Commercial Road
Melbourne, Victoria 3004
Australia

E-mail: sharon.lewin@monash.edu; s.lewin@alfred.org